68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH

NCT03189953 · Completed

Last updated 2026-05-28

This clinical trial is testing a new imaging method using 68Ga-NODAGA-exendin-4 PET/CT to detect insulinomas in adults with suspected or known insulinoma.

Status Completed The study has finished.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design open-label (no blinding) diagnostic study

Participants 56 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2015-04 · est. completion 2021-05

What this study is testing ClinicalTrials.gov NCT03189953 ↗

Description as written by the study sponsor.

In order to improve the sensitivity and specificity of pre-operative imaging localization of foci in adult endogenous hyperinsulinemic hypoglycaemia (AHH) we aim to evaluate a novel promising imaging compound targeting the glucagon-like peptide-1 receptor (GLP-1R), 68Ga-NODAGA-exendin 4. With the currently used imaging techniques, only about 70-80% of insulin producing pancreatic neuroendocrine tumors (IPPNET) can be successfully visualized. Therefore, we propose to compare GLP-1R PET imaging to the standard imaging techniques in patients scheduled for surgical removal of the tumour. These highly relevant data will allow us to interpret the benefits of GLP-1R-imaging over other imaging techniques for the diagnosis of IPPNET in AHH patients. Since pre-operative localization of foci in AHH remains challenging and frequently still leading to futile surgery or unnecessary partial pancreatectomy, a more sensitive and specific imaging technique would be of great value.

Treatments tested

68Ga-NODAGA-exendin 4 PET/CT Radiation

68Ga-NODAGA-exendin 4 PET/CT

Main thing measured	Tumor visualization by 68Ga-NODAGA-exendin-4 PET/CT and standard imaging
Sponsor	Radboud University Medical Center
Conditions studied	Insulinoma
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03189953 ↗